Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial

Compugen

05/07/2024 11:16

** U.S.-listed shares of Israel-based therapy developer
Compugen  CGEN.TA  fall ~3% to $1.62 premarket
    ** Switzerland-based Roche's  ROG.S  drug tiragolumab, which
is part of a new class of drugs known as anti-TIGIT, failed a
lung cancer treatment trial on Thursday
    ** CGEN has colorectal, ovarian and lung cancer treatments
in development that work by acting on the TIGIT receptor, which
suppresses the proliferation and activation of cells of the
immune system
    ** Up to last close, stock down 15.6% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))